Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...

Expand your screen space with the best monitor for a dual-screen setup. Whether you're hooking up a second display to your desktop or laptop, these are the screens I recommend checking out.

Companies outside the U.S. often pursue a dual listing in New York to widen ... seek answers on Novo Nordisk's next-gen obesity drug CagriSema 6:23 AM UTC Diageo estimates its operating profit ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss treatment. Novo had set a target for patients to lose 25% of their body weight on average over 68 weeks.

Well, it was the age-old bane of pharma firms, namely disappointing late-stage clinical trial results. In this case, the culprit was CagriSema, the company’s potential next-generation weight-loss ...

Love it or hate it, BOA is here to stay in ski boots. In fact, a handful of brands are getting rid of buckles entirely on some of the boots with the introduction of the new Dual BOA® Fit System. Yep, ...

A promising strategy to reduce errors entails the use of so-called dual-type qubits. These are qubits that can encode quantum information in a system across two different types of quantum states.

Now, here comes a dual-screen e-reader named inkReader duo which is in the form of a smartphone having twin E Ink displays. What that means is there actually are two separate E Ink displays at ...

Other drug companies are working on their own competitors to Ozempic, such as Boehringer Ingelheim and Zealand Pharma’s dual agonist ... that their drug candidate CagriSema (a mix of ...